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Abstract
Constrictive bronchiolitis is a bronchiolar airway disease that surrounds the lumen with fibrotic
concentric narrowing and obliteration. The mosaic pattern seen on the expiratory high-resolution
chest CT scan is diagnostic in an individual with shortness of breath, early inspiratory crackles, and
irreversible airflow obstruction. Swyer-James-MacLeod syndrome is no longer considered a
congenital disorder but as constrictive bronchiolitis detected in young adults who had infectious
pneumonia during infancy. For lung transplant recipients, tacrolimus continues to be an important
immune suppression medication, extracorporeal photopheresis may improve the decline of
pulmonary function, and azithromycin may be effective in some lung transplant recipients for
treatment of bronchiolitis obliterans syndrome for prevention of constrictive bronchiolitis.
Introduction and context
Constrictive bronchiolitis is a small airway fibrotic
respiratory disease. Clinicians use the term constrictive
bronchiolitis, bronchiolitis obliterans, or obliterative
bronchiolitis. The pathologist uses the term constrictive
bronchiolitis and will report the lesion with or without
airway obliteration. The clinically significant disease is
associated with the fibrotic obliteration of the bronchiolar
airways.This fibrotic constrictivelesion develops externally
to the airway lumen, constricting the airway in a concentric
manner with eventual obliteration of the lumen. This is
distinct from the inflammatory proliferative lesion that
develops internally from the airway wall, filling the lumen
with an inflammatory polypoid lesion or buds of
granulation tissue, and referred to as proliferative bronch-
iolitis. The fibrotic constrictive bronchiolitis involves the
mid-bronchiole region. The inflammatory proliferative
bronchiolitis lesion may involve the mid-bronchiole
region, but usually involves the distal bronchioles extend-
i n gi n t oa l v e o l a rs p a c e s ,a n di sr e f e r r e dt oa sb r o n c h i o l i t i s
obliterans organizing pneumonia (BOOP) [1].
Constrictive bronchiolitis is a peribronchiolar fibrotic
process that surrounds, rather than fills, the lumen with
concentric narrowing and obliteration. The lesion pre-
ferentially involves membranous bronchioles and spares
distal respiratory bronchioles. Constrictive bronchiolitis
may be patchy, making the diagnosis difficult from a
transbronchial biopsy. The diagnosis is also difficult in
regions showing no bronchiolar inflammation and in
completely scarred, distorted bronchioles.
Shortness of breath is the most common presenting
symptom,althoughcoughmayoccurearly.Chestphysical
examination may be normal or show early inspiratory
crackles or inspiratory ‘squeaks’. The chest X-ray is often
normal or shows hyperinflation. Inspiratory and expira-
tory chest computed tomography (CT) scans can be
diagnostic in an appropriate setting, such as in an
individual who is a non-smoker without asthma. The
expiratory high-resolution chest CT (HRCT) scan shows a
‘mosaic’ pattern, which is a patchwork of high- and low-
density regions resulting from air-trapping by constricted
and partially obliterated bronchioles (Figure 1). Bronchi-
ectasis and bronchiolectasis represent severe scarring and
are late findings. Pulmonary function testing typically
shows irreversible airflow obstruction as measured by a
decrease in the forced expired volume in 1 second
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situations,arestrictivepatternmaybeseen,usuallycaused
by dynamic compression of the lungs caused by air-
trapping. The diffusing capacity may be normal or
decreased.
Constrictive bronchiolitis may either be a primary lesion
or a lesion associated with other lung diseases or
systemic disorders. Idiopathic constrictive bronchiolitis
is very rare. Toxic fume constrictive bronchiolitis
continues to be reported intermittently, recently from
mustard gas exposure and among food-flavoring workers
using the ketone butter flavoring diacetyl. The diagnosis
continues to be established using the ‘three-phase’ model
of the illness, beginning with an asymptomatic latency
period of a few hours after the exposure. The second,
acute phase is characterized by severe shortness of breath
and pulmonary edema in the form of acute respiratory
distress syndrome often requiring mechanical ventilation
in the intensive care unit. This acute phase is treated with
massive doses of intravenous corticosteroid therapy.
After resolution, the third phase begins as an asympto-
matic latency period of several days followed by
constrictive bronchiolitis with irreversible airflow
obstruction. After completion of a course of corticoster-
oids, this final phase of the illness is managed by an
active pulmonary rehabilitation program and a home
exercise program.
Constrictive bronchiolitis may occur from aspiration. An
unusual cause of deadly constrictive bronchiolitis has
been reported among women consuming juice from a
leafy Malaysian vegetable, Sauropus androgynus, which is
purchased from street vendors and used for weight
control. Post-infection constrictive bronchiolitis may
develop after viral pneumonia or Mycoplasma pneumo-
nia. Constrictive bronchiolitis caused by drugs is rare and
limited to penicillamine, gold, and possibly 5-fluorour-
acil. Connective-tissue-related constrictive bronchiolitis
occurring among individuals with rheumatoid arthritis
and scleroderma is rare, but may cause disabling
respiratory symptoms. Constrictive bronchiolitis has
been reported in patients with inflammatory bowel
disease (caused by ulcerative colitis or Crohn’s disease),
Stevens-Johnson syndrome, paraneoplastic autoimmune
multi-organ syndrome, and neuroendocrine cell hyper-
plasia. Constrictive bronchiolitis may occur in allogeneic
marrow transplantation recipients and is preceded by
chronic graft-versus-host disease (GVHD). Constrictive
bronchiolitis as a result of stem cell transplantation may
occur in a small percentage of patients. Post-lung
transplantation constrictive bronchiolitis continues to
be a major life-threatening complication, affecting up to
50-60%ofpatientswhosurvivefiveyearsaftertransplanta-
tion. A non-biopsy classification for bronchiolitis oblit-
erans syndrome (BOS) using, amongst other parameters,
various levels of FEV1 values has been established as a
useful clinical designation. This is a clinical classification
that may include both proliferative inflammatory
bronchiolitis limited to the mid-bronchiole airway,
which may be responsive to corticosteroid therapy and
macrolide therapy, and fibrotic constrictive bronchioli-
tis, which is not responsive.
Recent advances
Several recent studies examining various aspects of
constrictive bronchiolitis have been published in the last
two years and are outlined here. In particular, intermittent
reports oftoxicfumeconstrictivebronchiolitis continueto
be published; for example, as mentioned above, mustard
gas exposure as a cause has recently been reported [2].
It has also been revealed that rheumatoid-arthritis-
related constrictive bronchiolitis is not as rare as
previously thought, but continues to be poorly respon-
sive to therapy and has a poor prognosis. In a 2009
report from France of 25 individuals with rheumatoid
arthritis and obliterative bronchiolitis, most had severe
airflow obstruction, often with an FEV1 of less than one
liter, and did not improve when treated with corticoster-
oids [3]. The prognosis was poor: chronic respiratory
failure occurred in 40% of patients and four died.
Immunological-disease-related constrictive bronchiolitis
also continues to be reported. In a 2009 report from the
Figure 1. Inspiratory and expiratory high-resolution chest CT
scans showing the mosaic pattern diagnostic of constrictive
bronchiolitis
Inspiratory Expiratory
The scans are from a bone-marrow recipient who had shortness of breath
and an FEV1 (forced expired volume in 1 second) that revealed a severe
airflow obstruction. The chest X-ray was normal. The inspiratory HRCT
scan on the left shows mostly normal lung; however, the expiratory HRCT
scan on the right shows a mosaic pattern with regions of air trapping from
constricted and partially obliterated bronchioles, consistent with constric-
tive bronchiolitis. The scans were gratefully provided by Dr Ritu Gill,
Chest Radiology, Brigham and Women’s Hospital, Boston, MA, USA.
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tic autoimmune multi-organ syndrome developed con-
strictive bronchiolitis [4]. The three individuals had very
severe airflow obstruction, with FEV1 values of much less
than one liter, and the prognosis was poor. Two of them
died and the third has stable chronic respiratory failure.
Swyer-James-MacLeod syndrome with unilateral con-
strictive bronchiolitis has always been considered rare,
and now is no longer considered congenital in origin,
but caused by a respiratory infection occurring during
infancy and diagnosed during teenage years or later [5].
The respiratory infections during infancy include
measles, whooping cough, tuberculosis, Mycoplasma
pneumonia, influenza A, and adenovirus types 3, 7, and
21 [5].
HRCT scans continue to be important and valuable in
establishing the diagnosis of constrictive bronchiolitis
in all clinical settings. In a 2008 report from the Mayo
Clinic describing 29 patients, mosaic perfusion and air
trapping was seen in HRCT scans of all patients, whereas
chest X-rays were normal in one-third and showed
hyperinflation in just over one-half [6]. It is important to
obtain both inspiratory and expiratory HRCT images in
order to help visualize these characteristic abnormalities.
In this group of 29 patients, shortness of breath occurred
in all patients and cough in less than 20%. The prognosis
was poor: one patient improved, several stabilized, and
four died.
Reports regarding constrictive bronchiolitis after hema-
topoietic stem cell transplantation continue to be
published [7,8]. Chronic GVHD, which occurs in 30-
70% of allogeneic transplant recipients, is the major risk
factor. The prognosis is very poor after development of
this fixed airway lesion, with a survival rate of 13% at
fiveyears[7].Thetreatmentofconstrictivebronchiolitisis
similar to that of chronic GVHD – high-dose corticoster-
oids and augmentation of immunosuppressive therapy,
usually consisting of cyclosporine or tacrolimus.
Azathioprine has also been used. The treatment is
continued for 3-12 months, although 9 months is
probably sufficient [8]. Anti-tumor necrosis factor agents
have not yet been proven effective. Macrolides in the
form of azithromycin (250 mg three times weekly) may
be helpful for the bronchiole inflammatory component.
High-dose inhaled corticosteroid therapy may be help-
ful; however, the agent is blocked by obliterated
bronchioles and the high dose required may produce
systemic adverse reactions. A randomized study has not
yet been performed. Extracorporeal photopheresis ther-
apy for treatment of GVHD and constrictive bronchiolitis
may be helpful in these patients [8]. The prognosis
continues to be poor as less than 20% of patients
improveand65%diewithinthreeyearsofthediagnosisof
constrictive bronchiolitis regardless of therapies insti-
tuted, although lung transplantation can be considered
in select patients [7].
Constrictive bronchiolitis in lung transplant recipients
continues to plague surgeons and patients, and is the
main obstacle to long-term survival. Reports are pub-
lished on a monthly basis, most of which confirm
previous findings and treatment results. Gastroesopha-
geal reflux disease is a common finding among lung
transplant recipients. Among 59 lung recipients, 53
(90%) had reflux, of which 65% had abnormal acid
reflux and 27% had non-acid reflux [9]. By using
esophageal impedance, it was found that non-acid reflux
may be a cause of constrictive bronchiolitis [9]. If non-
acid reflux plays a role in lung transplant recipients, it
may be that the reflux leads to an alloimmune response
that causes the syndrome.
The six-minute walk test may be a useful tool for
assessing prognosis in lung transplant recipients who
have developed bronchiolitis obliterans syndrome. In a
2009 study, patients who walked farther than 330 meters
had a median survival of 1178 days compared to 263
days for lung recipients who walked less [10].
Tacrolimus is an important immunosuppressant medi-
cation for lung transplant recipients. Compared to
cyclosporine, patients treated with tacrolimus appear to
have similar survival and fewer acute rejection episodes
[11]. This study also revealed that tacrolimus-treated
patients may have a lower risk of constrictive bronchio-
litis, as this agent may decrease the occurrence of chronic
rejection [11]. However, some data regarding tacrolimus
and cyclosporine are conflicting, and there is no
consensus as to which is better. Studies showing the
inferiority of cyclosporine did not use the preferred
method of monitoring trough levels. In addition, some
reports have suggested that compliance with tacrolimus
appeared to be better than with cyclosporine. Both
tacrolimus and cyclosporine have significant toxicity and
are associated with increased risk of opportunistic
infections, hypertension, and renal insufficiency. New-
onset diabetes after transplantation appears to be more
common in lung transplant recipients treated with
tacrolimus.
In an immune suppression study of 120 consecutive lung
transplant recipients, the combination of tacrolimus and
azathioprine was similar to cyclosporine and mycophe-
nolate mofetil with regard to efficacy and frequency
of adverse reactions. [12]. The survival and rate of
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regimens when combined with interleukin-2 induction
therapy. Overall, studies in lung recipients have not
consistently identified one immunosupression regimen
to be superior to another and it is not clear that any have
a significant impact on the long-term development of
constrictive bronchiolitis.
Extracorporeal photopheresis is the removal of a
patient’s blood and its separation into leukocyte-
enriched and leukocyte-depleted blood components.
The buffy coat of leukocytes is exposed to ultraviolet
light in the presence of 8-methoxypsoralen in a photo-
activation chamber. Several events take place in the
chamber, including leukocyte apoptosis, changes in
dendritic cell populations, production of cytokines,
and induction of regulatory T cells [13]. Extracorporeal
photopheresis is an accepted therapy for prophylaxis and
treatment of acute cellular rejection in heart transplanta-
tion. Among 60 lung transplant recipients, a 2009 study
showed that extracorporeal photopheresis treatment
decreased the rate of FEV1 d e c l i n ea n dt h eF E V 1
improved in 25% of patients [13]. Extracorporeal
photopheresis was associated with a significant reduc-
tion in the rate of decline in lung function, which was
sustained over 6 and 12-month periods [13]. Large,
randomized clinical studies are needed to confirm these
results.
Macrolide antibiotics, such as azithromycin (250 mg,
three times weekly), can be effective treatment for
chronic inflammatory lung diseases such as bronchiec-
tasis, cystic fibrosis, and BOOP. A study of lung-
transplant-related BOS indicated that patients may be
classed as one of two phenotypes, one that shows early
lavage neutrophils and may be responsive to azithromy-
cin, and another without neutrophil inflammation that
is not responsive [14]. This is consistent with the
knowledge that constrictive bronchiolitis is a fibrotic
process that is not responsive to macrolides, whereas
inflammatory bronchiolar lesions are responsive to
macrolides. As this was a study of BOS and not a
histological diagnosis, the macrolide-responsive patients
may have had inflammatory bronchiolitis while the non-
responsive patients may have had fibrotic constrictive
bronchiolitis. An additional important finding about
azithromycin is that it may reduce gastroesophageal
reflux in lung transplant recipients, further decreasing the
risk of constrictive bronchiolitis [14].
Implications for clinical practice
These recent publications on constrictive bronchiolitis
have several implications. First, HRCT scans continue to
be very helpful for the diagnosis of constrictive
bronchiolitis in an individual with new onset airflow
obstruction, early inspiratory crackles, and a normal
chest X-ray. Second, constrictive bronchiolitis should be
considered in a patient with rheumatoid arthritis who
develops shortness of breath. The diagnosis can be
established by obtaining an expiratory HRCT scan. Third,
the Swyer-James-MacLeod syndrome is not a congenital
disorder but constrictive bronchiolitis that is detected in
young adults caused by a viral or bacterial infection
during infancy. Fourth, the six-minute walk test may be a
useful test for monitoring lung transplant recipients with
BOS. Fifth, although used since the 1990s, tacrolimus
appears to continue to be an important organ-transplant
immune suppression medication. Sixth, extracorporeal
photopheresis may be effective management for con-
strictive bronchiolitis in some patients. Finally, azithro-
mycin may be effective in a select group of lung
transplant recipients for prevention of BOS.
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